First Patient Dosed in Phase 2 Pediatric Trial Evaluating SAT-3247 for DMD The first participant has received treatment in the BASECAMP trial evaluating SAT-3247, an investigational AAK1 inhibitor for DMD.

@satellosbio.bsky.social announced that the first patient has been dosed in a phase 2 pediatric #ClinicalTrial evaluating SAT-3247, an investigational therapy for #Duchenne muscular dystrophy (#DMD).

Learn more: https://bit.ly/46cLHQH

#RareDisease #SAT3247 #MedSky

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Source: ir.satellos.com/news/news-de...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #satellos #sat3247 #sat-3247